ArticleFrontiers in oncology2022

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.

David S Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.